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The MED-1,2 GATA factors contribute to speciﬁcation of E, the progenitor of the Caenorhabditis elegans
endoderm, through the genes end-1 and end-3, and in parallel with the maternal factors SKN-1, POP-1
and PAL-1. END-1,3 activate elt-2 and elt-7 to initiate a program of intestinal development, which is
maintained by positive autoregulation. Here, we advance the understanding of MED-1,2 in E speciﬁca-
tion. We ﬁnd that expression of end-1 and end-3 is greatly reduced inmed-1,2() embryos. We generated
strains in which MED sites have been mutated in end-1 and end-3. Without MED input, gut speciﬁcation
relies primarily on POP-1 and PAL-1. 25% of embryos fail to make intestine, while those that do display
abnormal numbers of gut cells due to a delayed and stochastic acquisition of intestine fate. Surviving
adults exhibit phenotypes consistent with a primary defect in the intestine. Our results establish that
MED-1,2 provide robustness to endoderm speciﬁcation through end-1 and end-3, and reveal that gut
differentiation may be more directly linked to speciﬁcation than previously appreciated. The results
argue against an "all-or-none" description of cell speciﬁcation, and suggest that activation of tissue-
speciﬁc master regulators, even when expression of these is maintained by positive autoregulation, does
not guarantee proper function of differentiated cells.
& 2015 Elsevier Inc. All rights reserved.Introduction
The robustness of embryonic development is reﬂected in the
structure of the underlying gene regulatory networks (GRNs) that
drive progenitor speciﬁcation and tissue differentiation (Davidson
and Levine, 2008). In the nematode, Caenorhabditis elegans, embryos
follow a highly stereotyped pattern of cell divisions (Sulston et al.,
1983). By the 8-cell stage, the endodermal progenitor E becomes
speciﬁed to generate the 20 cells of the juvenile intestine (Sulston
et al., 1983). The identiﬁcation of the key regulators of E speciﬁcation
has made the endoderm GRN one of the best-understood networks
in this animal (Maduro, 2008; Maduro and Rothman, 2002), making
it an excellent system in which to probe regulatory mechanisms of
developmental robustness. In this paper, through a combination of
targeted lesions and detailed phenotyping, we show that disrupting
the regulatory abilities of a set of putatively minor players in the.endoderm GRN leads to irredeemable intestinal defects that persist
through adulthood.
Speciﬁcation of the E cell occurs through the sequential and
combinatorial activities of a set of transcription factors (summar-
ized in Fig. 1A). Input from the maternal factors SKN-1, the TCF
protein POP-1 (with its co-activator, the divergent β-catenin SYS-
1) and the Caudal-like regulator PAL-1, together cause activation of
the redundant genes end-1 and end-3 in the early E lineage
(Bowerman et al., 1992; Maduro et al., 2005b; Shetty et al., 2005).
SKN-1 activates end-1,3 in part through activation of med-1 and
med-2 (Maduro et al., 2001). In turn, MED-1,2 bind to end-1,3 to
contribute to their activation (Broitman-Maduro et al., 2005;
Maduro et al., 2002). Input from med-1,2 is not essential for gut
speciﬁcation, as loss of these genes results in 15–50% of embryos
that lack endoderm (Goszczynski and McGhee, 2005; Maduro
et al., 2007; Maduro et al., 2001).
POP-1 has a dual role in endoderm speciﬁcation: It both acti-
vates E speciﬁcation in E, and represses E speciﬁcation in the sister
cell of E, called MS (Shetty et al., 2005). Activation by POP-1 results
end-3::GFP
med-1,2(-)
med-1,2(-)
resc.
resc.
end-1::GFP
SKN-1
MED-1,2
END-3
END-1
ELT-7
ELT-2
POP-1PAL-1 /SYS-1
**
ine genesintest
S
P
E
C
IF
IC
A
TI
O
N
D
IF
FE
R
E
N
TI
A
TI
O
N
E E2
E2
E2 E4
E4
E20
Fig. 1. Endoderm speciﬁcation pathway in C. elegans and requirement of MED-1,2 for high levels of end-1 and end-3 reporter expression. (A) Gene Regulatory Network for
speciﬁcation of E showing convergent upstream inputs of SKN-1, POP-1/SYS-1, and PAL-1 (Maduro, 2008). SKN-1 is a bZIP/Homeodomain factor (Blackwell et al., 1994), POP-1
is the TCF-like C. elegans Wnt effector (Lin et al., 1998), and PAL-1 is a Caudal-like homeodomain protein (Hunter and Kenyon, 1996). All of med-1, med-2, end-1, end-3, elt-7
and elt-2 encode C4 zinc ﬁnger GATA type transcription factors, although MED-1 and MED-2 belong to a divergent novel subclass with a unique binding site (Lowry and
Atchley, 2000; Lowry et al., 2009). On the right, a 12-cell embryo is shown with the E nucleus showing GFP ﬂuorescence, above a newly-hatched L1 larva (approximately to
scale) showing the nuclei of the 20 E descendants in the intestine. The embryo and larva images are from a previous work (Maduro and Rothman, 2002). (B, C) Expression of
an integrated end-3::GFP reporter (wIs137) in rescued and non-rescued med-1(ok804); med-2(cxTi9744) embryos. Rescued embryos carry the free duplication irDp1, which
rescues med-1,2() lethality and whose presence was ascertained by expression of an unc-119::YFP reporter on irDp1 at a later time point (Maduro et al., 2007). (D, E)
Expression of an integrated end-1::GFP::H2B reporter (teIs46) (Shetty et al., 2005) in the same med-1,2(); irDp1 strain. In panels C and E, embryos carrying irDp1 are
outlined in red, while those lacking irDp1 are outlined in yellow. A C. elegans embryo is approximately 50 mm long.
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4-cell stage blastomere P2 and EMS, the mother cell of E (Roche-
leau et al., 1997; Thorpe et al., 1997). Transduction of these signals
causes nuclear export of POP-1 in E, allowing the remaining
nuclear POP-1 to interact with limiting amounts of nuclear SYS-1,
forming a bipartite activator (Huang et al., 2007; Phillips et al.,
2007). In the MS nucleus, the ratio of POP-1 to SYS-1 is high,
resulting in repression of endoderm fate (Huang et al., 2007;
Maduro et al., 2007; Shetty et al., 2005). A recent report identiﬁed
a requirement for conserved cis-regulatory sites, proximal to POP-
1 sites, to which POP-1/SYS-1 bind during Wnt-dependent target
gene activation (Bhambhani et al., 2014). These Helper sites appear
to be absent in end-3, suggesting that the activation component of
POP-1/SYS-1 in E speciﬁcation occurs primarily through end-1
(Bhambhani et al., 2014; Robertson et al., 2014). While Wnt-acti-
vated POP-1 contributes to endoderm speciﬁcation, it is not
essential, as 495% of pop-1-depleted embryos still make gut (Lin
et al., 1995; Maduro et al., 2007; Maduro et al., 2005b). Like the
contribution of pop-1, positive input into E speciﬁcation by the
Caudal-like factor PAL-1 can be detected by enhancement of
the endoderm defect of skn-1-depleted embryos by pal-1(RNAi),
though the details of PAL-1 regulation of the end genes are not
known (Maduro et al., 2005b).
The zygotic end-1 and end-3 genes together specify the endo-
derm fate (Maduro et al., 2005a; Zhu et al., 1997). While end-1 and
end-3 both encode similar GATA factors, they are not completely
redundant. First, mutation of either gene individually results in
slightly different phenotypes (Boeck et al., 2011; Maduro et al.,
2005a, 2007). Second, expression of end-3 precedes that of end-1
and END-3 activates end-1 (Baugh et al., 2003; Maduro et al.,
2007). The ENDs activate the intestine differentiation factors elt-2
and elt-7, of which ELT-2 appears to be the major regulator of
intestinal identity (Fukushige et al., 1998; McGhee et al., 2009;
Sommermann et al., 2010). With the exception of POP-1, which is
present throughout development in many lineages (Huang et al.,
2007; Lin et al., 1998), the endoderm speciﬁcation factors through
the ends are expressed only transiently, while elt-2 and elt-7
maintain their expression by autoregulation (and cross-regulation)
for the lifetime of the animal (Bowerman et al., 1993; Fukushige
et al., 1998; Hunter and Kenyon, 1996; Maduro et al., 2005a, 2001;
Sommermann et al., 2010). Hence, endoderm development
appears to transition from speciﬁcation to differentiation with the
activation of elt-2 and elt-7.The paradigm for gut speciﬁcation has been that it is a "binary"
fate choice. In particular, loss of skn-1 results in terminally-arrested
embryos that contain either a cluster of gut-like cells or no gut cells
(Bowerman et al., 1992). Studies of the Wnt/MAPK pathway also
describe terminally arrested embryos as either having gut or not
(Rocheleau et al., 1997; Thorpe et al., 1997). At the level of gene
expression, gut speciﬁcation has been proposed to occur through a
threshold mechanism. While wild-type embryos accumulate sufﬁ-
cient end-1 mRNA (and presumably, END-1 protein) to activate elt-2,
embryos lacking skn-1 activity exhibit variability in end-1 mRNA
levels, such that only those embryos reaching a threshold number of
end-1 transcripts are able to activate elt-2 (Raj et al., 2010).
In contrast to binary speciﬁcation, other studies have provided
evidence that perturbation of endoderm speciﬁcation can have
more complex effects on the gut. First, the cell division patterns of
the E lineage can be uncoupled from E fate, as has been observed
with reduction of function of Wnt/MAPK components (Putzke and
Rothman, 2010; Robertson et al., 2014), gain-of-function mutations
in the cell cycle regulator gene cdc-25.1 (Clucas et al., 2002; Kostic
and Roy, 2002), and end-3 single mutants (Boeck et al., 2011).
Second, in embryos lacking med-1 and med-2, we have observed
variations in the number of elt-2::GFP-expressing nuclei in late-
stage embryos that make gut, from only a few to greater than 30
(Maduro et al., 2007). We have interpreted aberrant gut cell
numbers in med-1,2() mutant embryos to mean that MED-1,2
are required for most normal gut speciﬁcation (Maduro et al.,
2007), while others have used a binary deﬁnition of speciﬁcation
to conclude that MED-1,2 have no major role in gut speciﬁcation
(Captan et al., 2007; Goszczynski and McGhee, 2005).
Standard approaches have made it difﬁcult to resolve the role of
the MEDs in endoderm speciﬁcation. First, RNAi of med-1 and med-2
by direct dsRNA injection is effective only across a narrow time
interval of progeny embryos (Maduro et al., 2001). Second, there is
some evidence that a component ofmed function might be maternal,
such that homozygous med-1,2() embryos derived from a mother
complemented for med(þ) activity exhibit a maternal rescue of
endoderm speciﬁcation (Maduro et al., 2007). In those studies, a
strain was made that uses a free duplication, irDp1, to abolish this
maternal component while rescuing embryonic med-1,2 lethality
(Maduro et al., 2007). However, it has been argued that other genes
inserted on irDp1 prevent appearance of gut granules, artiﬁcially
increasing the number of late-stage embryos scored as lacking gut
(Captan et al., 2007). As well, other work has not detected med-1/2
transcripts prior to the four-cell stage (Raj et al., 2010). Third, because
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the E lineage could result from failed speciﬁcation or simply because
overall morphogenesis failed to occur. Loss of skn-1 or Wnt/MAPK
components also results in arrested embryos that have failed to
complete morphogenesis (Bowerman et al., 1992; Lin et al., 1995;
Rocheleau et al., 1997; Thorpe et al., 1997).
Here we investigate the role of the MEDs in E speciﬁcation by
directly assessing the consequences of loss of MED-dependent
regulation of only end-1 and end-3, without affecting the role of
the MEDs in MS speciﬁcation. We examine expression of end-1
and end-3 reporters in med-1,2() embryos and ﬁnd that both are
greatly reduced. We generated strains in which the known MED-
1,2 binding sites have been mutated in the context of single-copy
end-1 and end-3 transgenes and introduced these into an end-1
end-3 double mutant background. We ﬁnd that without MED sites,
speciﬁcation of gut becomes highly dependent on pop-1 and pal-1,
and slightly less so on skn-1. When MED sites have been mutated,
at least some gut speciﬁcation occurs in 75% of embryos, and as
with prior analysis using genetic loss of med-1,2, 95% of embryos
make aberrant numbers of elt-2::GFP-expressing nuclei. These
results establish that the MED sites, and hence med-1,2, are
required for proper activation of end-1,3 and normal gut devel-
opment in the vast majority of embryos, and that the SKN-1/MED-
1,2 pathway functions in parallel with both POP-1 and PAL-1.
Finally, we make the unexpected ﬁnding that among those ani-
mals lacking MED sites in end-1 and end-3 that develop to adult
stage, many exhibit defects consistent with a primary defect in the
intestine. This suggests that normal adult intestine function
requires robust embryonic activation of end-1,3 by MED-1,2.Materials and methods
Genetics
C. elegans animals were grown on E. coli OP50 and handled
according to standard methods. The reference strain was N2. Muta-
tions and transgenes were as follows. LG I: ttTi4348 [Mos], irSi10 [end-
3(1234)þCbr-unc-119(þ)], irSi11 [end-3(1234)þ
Cbr-unc-119(þ)], irSi13 [end-3(þ)þCbr-unc-119(þ)], irSi25 [end-3
(1þ2þ3þ4)þCbr-unc-119(þ)], irSi26 [end-3(1234þ)þCbr-
unc-119(þ)], oxSi259 [eft-3p::GFPþCbr-unc-119(þ)]. LG II: ttTi5605
[Mos], irSi7 [end-1(12)þCbr-unc-119(þ)], irSi8 [end-1(12)þ
Cbr-unc-119(þ)], irSi9 [end-1(þ)þCbr-unc-119(þ)], irSi19 [end-1
(12)þCbr-unc-119(þ)], irSi20 [end-1(12)þCbr-unc-119(þ)],
irSi21 [end-1(12)þCbr-unc-119(þ)], oxIs322 [myo-2p::mCherry::
H2Bþmyo-3p::mCherry::H2BþCbr-unc-119(þ)]. LG III: unc-119(ed3),
unc-119(ed4), unc-119(ed9), med-2(cxTi9744). LG IV: cxTi10882 [Mos],
him-8(e1489), irSi24 [pept-1::mCherry::H2BþCbr-unc-119(þ)]. V: end-
1(ok558), end-3(ok1448), end-3(zu247), itDf2, irIs91 [unc-119::
mCherry], wIs137 [end-3::END-3[P202L]::GFPþrol-6D]. X: lon-2(e678),
med-1(ok804), wIs28 [elt-2::GFPþrol-6D]. Unmapped: teIs46 [end-1::
GFP::H2Bþunc-119(þ)]. Other: irDp1(III; f) [unc-119::YFP, med-1(þ),
unc-32(þ)], nT1 [unc-?(n754) let-?] (IV;V). The ok558 and ok1448
mutations delete the DNA-binding domains of end-1 and end-3,
respectively, and are null alleles for both genes; end-1,3() embryos
fail to activate elt-2 and do not make gut (Owraghi et al., 2010).
Plasmids and cloning
Cloning was performed using standard methods. MosSCI target-
ing vectors for end-1 were made using pCFJ151, and for end-3,
pCFJ352. Transgenes were constructed in steps using pUC19 and
pBluescript, then introduced into the targeting vectors by restriction
digestion and cloning. The MED-site mutated end-1 reporter was
constructed through two rounds of PCR and cloning using divergent,overlapping primers to introduce the indicated changes (Fig. 2D).
Mutated MED sites in end-3 were obtained using a combination of
mutagenic PCR primers and de novo synthesis of part of the end-3
promoter by Integrated DNA Technologies (Coralville, IA). To make a
pept-1::mCherry reporter, 1830 bp upstream of pept-1/K04E7.2 were
ampliﬁed by PCR and cloned into a vector encoding the mCherry
coding region (with three introns) fused to the his-66 coding region
and the unc-54 3′UTR, using the vector pPD95.67 as a backbone. The
recombinant transgene fusion was then cloned into the targeting
vector pCFJ178. Constructs were conﬁrmed by sequencing. Further
cloning details are available on request.
Transgenesis
Chromosomal insertions were made using the MosSCI direct
insertion protocol into strains EG4322, EG5003 and EG6701 with
coinjection plasmids pCFJ601 (eft-3::Mos1 transposase) or pJL43.1
(glh-2::Mos1 transposase), pGH8 (rab-3::mCherry), pCFJ90 (myo-
2::mCherry) and pCFJ104 (myo-3::mCherry), as described (Frok-
jaer-Jensen et al., 2012, 2008). For some insertions we included
pMA122 (hs-peel-1) as an inducible negative selection marker, but
in our hands it was more effective to screen for insertion candi-
dates by absence of the coinjected mCherry markers. For some
experiments, a lon-2 mutation was introduced into the unc-119;
Mos1 strains to facilitate injections. MosSCI end-1 transgenes were
targeted to the ttTi5605 II site, end-3 transgenes to the ttTi4348 I
site, and the pept-1 reporter into the cxTi10882 IV site. Homo-
zygous chromosomal insertion was conﬁrmed by 100% transmis-
sion of rescue of the unc-119 phenotype and PCR to detect the
inserted transgene in its expected genomic context. We sequenced
overlapping PCR products to conﬁrm intactness of the inserted
transgenes. Successful recovery of end transgene genomic inser-
tions occurred at a frequency of 20% that of the control unc-122::
GFP targeting plasmid pCFJ68 (Frokjaer-Jensen et al., 2008). The
choice to insert the end transgenes parallel to the Cb-unc-119
rescue marker was deliberate, as attempts to insert transgenes in
which the direction of end transcription was inverted (i.e. con-
vergent to the Cb-unc-119 gene) resulted in high embryonic leth-
ality following injection with very few (or no) rescued F1s. In our
hands, approximately 20% of all single-copy insertion candidates
failed to breed true for unc-119 rescue after several generations
even though PCR showed these transgenes to be chromosomally
inserted; such strains were eliminated from further consideration.
Finally, we note that multiple independent insertions using the
same targeting plasmids were indistinguishable in phenotype
assays, suggesting they are identical. For simplicity, we collectively
refer to the end-1(12) insertions (irSi7, irSi8, irSi20, irSi21) as Si
[end-1(MED)] and the end-3(1234) insertions (irSi10,
irSi11) as Si[end-3(MED)].
Reporters for end-1 and end-3
The end-1 reporter teIs46 carries 2165 bp upstream of the pre-
dicted start codon of end-1, from the start of the coding region of the
nearest upstream gene on the other strand, extending through the
middle of the coding region of end-1 (Shetty et al., 2005). The end-3
reporter wIs137 contains the nearest upstream gene, aip-1, and the
entire end-3 gene with the P202L substitution (present in the
apparent null allele zu247) in the end-3 DNA-binding domain
(Maduro et al., 2005a).
Strain construction
Worm strains were constructed by standard methods. Muta-
tions and transgenes were combined using standard crosses with
a reciprocal balancer strategy to simplify strain recovery. To
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double mutant background, myo-2::mCherry (oxIs322) and eft-3::
GFP (oxSi259) transgenes, inserted at the ttTi5605 II and ttTi4348 I
sites, respectively, were used as balancers. We introduced oxIs322
and oxSi259 into an end-1,3() background rescued by an extra-
chromosomal array (irEx498) carrying end-3(þ) and an unc-119::
mCherry reporter (Owraghi et al., 2010). In parallel, an integrated
unc-119::mCherry array (irIs91 V) was introduced into the single-
copy end transgene strains as a balancer for the end-1 end-3
double mutant chromosome. By crossing strains together, the
absence of reporter balancers could be used for counter-selection
to conﬁrm recovery of strains homozygous for either or both end
transgenes and the end-1,3() chromosome. For introduction of
only one of the single-copy end-1 or end-3 transgenes into an end-
1,3() background, either the oxIs322 or oxSi259 balancer was
used as appropriate. The end-1,3() strains carrying only end-1
(MED) or end-3(MED) single-copy transgenes were maintained
by an extrachromosomal rescuing array carrying a ﬂuorescent
reporter. The end-1,3(); Si[end-1(MED)] strain could be main-
tained in the absence of the array, though with a very low per-
centage of viable progeny. A him-8(e1489) background was used as
a source of males, and was conﬁrmed to be absent from strains by
ensuring the absence of the Him phenotype in subsequent gen-
erations. As noted in the text, the end-1(ok558) end-3(ok1448) V;
irSi[end-1(MED)] II; irSi[end-3(MED)] I genotype will be
abbreviated as end-1,3(MED) for simplicity. To generate itDf2
strains carrying the end-1 and end-3 transgenes, oxIs322 and
oxSi259 were ﬁrst introduced into an itDf2; nT1 strain. This was
then crossed with males carrying the single-copy end-1 and end-3
transgenes and irIs91, and balanced itDf2/irIs91; end-1 transgene;
end-3 transgene hermaphrodites were obtained. These were then
self-fertilized and non-irIs91 progeny embryos (homozygous for
itDf2) were scored for gut.
Additional end-1 and end-3 expression assays in med-1,2
mutant embryos were performed as follows. We constructed med-
1; med-2; irEx138 [med-1(þ), unc-119::CFP] strains carrying either
teIs46 [end-1::GFP] or wIs137 [end-3::GFP]. The irEx138 array is lost
meiotically in 2% of hermaphrodites. We singled out young
hermaphrodites in groups of 20–50 for each strain and identiﬁed
germline mosaics by observing plates that failed to pass the array
to the ﬁrst 50 progeny as evidenced by the failure of any of the
embryos to hatch, and conﬁrmed by the absence of unc-119::CFP
expression in any of these. Progeny embryos were then conﬁrmed
to be at a stage appropriate for expression of end-1::GFP or end-3::
GFP and examined by ﬂuorescence microscopy. We found that
27/27med-1,2(); teIs46 embryos failed to express end-1::GFP and
31/32 med-1,2(); wIs137 embryos failed to express end-3::GFP.
RNAi experiments
RNAi by bacterial feeding was performed as described, using
cDNA clones for skn-1, pop-1 or pal-1 in the E. coli strain HT115
(Kamath et al., 2001; Maduro et al., 2005b). Direct dsRNA
injection for these same genes was performed as described
(Maduro et al., 2005b). Developmental arrest was observed in
495% of progeny embryos, which was also conﬁrmed to display
the expected phenotypes by DIC for individual knockdown of
skn-1, pop-1 or pal-1 (Bowerman et al., 1992; Hunter and Ken-
yon, 1996; Lin et al., 1998, 1995).
Developmental progression experiments
Twenty adults each of the end-1,3(); Si[end-1(þ)]; Si[end-3
(þ)] and end-1,3(); Si[end-1(MED)]; Si[end-3(MED)] strains
were placed on two 3-cm plates (10 per plate), allowed to lay eggs
for two hours, then removed. Any embryos older or younger thanthe bean stage were removed. Plates were grown in parallel
between 20 °C and 23 °C. Development was monitored every two
hours starting 40 h after the eggs had been laid. Animals that had
reached young adult stage as judged by vulva morphology, pre-
sence of a germline, but lacking embryos, were scored and
removed.
Microscopy, imaging and scoring for gut
All phenotypes were scored at 20 °C. Embryo imaging was per-
formed as described (Owraghi et al., 2010). Staining and imaging for
smFISH experiments were performed as described (Raj et al., 2010).
Transcript counts were estimated from the images using custom
software (Rifkin, 2011; Wu and Rifkin, 2015). The endogenous end-1
and end-3 mRNAs are not detected because the majority of the
smFISH probes are deleted by the end-1(ok558) and end-3(ok1448)
mutations (data not shown). Gut was scored as present in an embryo
if a patch of gut granule-like material was observed under polarized
light. We previously observed that 11–13% of embryos double mutant
for end-1 and end-3 exhibit gut granule-like material localized to the
excretory canal (Owraghi et al., 2010). However, we are able to dis-
tinguish true gut granules by conﬁrming nuclear morphology of cells
associated with them, or expression of integrated pept-1::mCherry::
H2B (irSi24) or elt-2::GFP (wIs84) reporters (Fukushige et al., 1998;
Nehrke, 2003). We found that in embryos with very little gut,
expression of wIs84 becomes apparent in a small number of nuclei
that appear to be in the gonad primordium based on morphology
(Chang et al., 2005) and on the lack of association with gut granules.
Such expression was not exhibited by irSi24, conﬁrming that it is
external to the gut. To score number of gut nuclei in adults, end-1,3
(); Si[end-1(þ)]; Si[end-3(þ)]; irSi24 [pept-1::mCherry::H2B] and
end-1,3(); Si[end-1(MED)]; Si[end-3(MED)]; irSi24 [pept-1::
mCherry::H2B] strains were grown in parallel. Late L4 stage animals
were examined by ﬂuorescence microscopy and scored for number of
mCherry(þ) nuclei.Results
Expression of full-length end-1 and end-3 reporters is dependent on
MED-1,2
Prior work has shown that end-1 and end-3 are activated by
multiple factors (Fig. 1A) (Broitman-Maduro et al., 2005; Maduro
et al., 2005a; Maduro et al., 2002; Robertson et al., 2014; Shetty et al.,
2005). The promoters of both genes contain various binding sites for
these factors as shown in Fig. 2A; an analysis of the frequency of
these sites is shown in Table S1. We have previously shown that the
DNA-binding domain of MED-1 interacts directly with binding sites
in end-1 and end-3 of sequence 5'-GTATACTYYY-3', and that these
sites are required for GFP expression using "minimal" promoters
o200 bp (Broitman-Maduro et al., 2005; Maduro et al., 2002). To
evaluate the requirement for med-1,2 function in the context of full-
length promoters, we examined expression of integrated, full-length
end-1 and end-3 reporters (see Materials and methods section). We
introduced these separately into a med-1(ok804); med-2(cxTi9744)
double null mutant strain that carries irDp1, a free duplication res-
cuing the lethality of loss of med-1 and med-2, and whose presence
can be detected by expression of an unc-119::YFP transgene (Maduro
et al., 2007). The partial endoderm defect of med-1,2() mutants,
and the multitude of other regulatory inputs into both end-1 and
end-3 (Fig. 2A), predicted that the expression of the end-1 and end-3
reporters would exhibit only a minor reduction of expression when
chromosomal med-1,2 function is lost. Contrary to this prediction,
expression of both reporters was reduced to background or near-
background levels in med-1,2() embryos (n¼30 for each;
M.F. Maduro et al. / Developmental Biology 404 (2015) 66–7970representative embryos shown in Fig. 1B–E). We performed similar
experiments in med-1,2() strains rescued by an extrachromosomaldistance upstream
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Table 1
Endoderm production in C. elegans strains.
Genotype % of embryos with gut (n)a
Wild-type (N2) 100% (n4500)b
end-1(ok558) 100% (322)b
end-3(ok1448) 95% (155)b
end-1(ok558) end-3(ok1448) 0% (190)b
end-1,3()c; Si[end-1(þ)] 96% (133)
end-1,3(); Si[end-1(MED)] 28% (98)
end-1,3(); Si[end-3(þ)] 100% (87)
end-1,3(); Si[end-3(1þ2þ3þ4)] 100% (253)
end-1,3(); Si[end-3(1234þ)] 85% (271)
end-1,3(); Si[end-3(MED)] 0% (93)
end-1,3(); Si[end-1(þ)]; Si[end-3(þ)] 100% (169)
end-1,3(); Si[end-1(MED)]; Si[end-3(þ)] 100% (139)
end-1,3(); Si[end-1(þ)]; Si[end-3(MED)] 100% (214)
end-1,3(); Si[end-1(MED)];Si[end-3(MED)] 75% (459)
itDf2 0% (123)
itDf2; Si[end-1(þ)]; Si[end-3(þ)] 100% (126)
itDf2; Si[end-1(MED)]; Si[end-3(MED)] 75% (198)
a Scored by presence of any amount of gut granules visualized by polarized
light birefringence.
b From Owraghi et al., 2010, included here for comparison.
c end-1,3(-) denotes the end-1(ok558) end-3(ok1448) double-mutant genotype.
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absent in all med-1,2() embryos, as such embryos make gut most
of the time. The failure to observe signiﬁcant end reporter
expression may be due to the multicopy nature of the transgenes,
or the inability to detect very low levels of expression. We hypo-
thesized that a more direct assessment of the contribution of
MED-1,2 regulation of end-1 and end-3 could be made by evalu-
ating gut speciﬁcation when the MED-1,2 cis-regulatory sites have
been mutated in the end genes. To perform these experiments, we
cloned the complete end-1 and end-3 genes into separate targeting
vectors for single-copy insertion by the MosSCI protocol (Fig. 2B)
(Frokjaer-Jensen et al., 2012, 2008). The end-1 gene contains two
MED binding sites (5'-GTATACTYYY-3', Fig. 2C), while end-3 con-
tains four (Broitman-Maduro et al., 2005; Lowry et al., 2009). We
made additional transgenes containing point mutations that are
predicted to interfere with binding by the MED-1 DNA-binding
domain (Fig. 2D) (Lowry et al., 2009). As med-1 and med-2 appear
to have redundant function, and the DNA-binding domain of MED-
2 differs from that of MED-1 by only a single amino acid, it is likely
that both proteins recognize the same site.
Single-copy transgenic end-1 and end-3 are proxies for the endo-
genous loci
We inserted the end-1 and end-3 transgenes into deﬁned sites on
chromosomes II (ttTi5605) and I (ttTi4348), respectively, as both
locations are known to be compatible with normal expression of
introduced genes (Frokjaer-Jensen et al., 2012). Separate insertions
mimic the endogenous end loci, as end-1 and end-3 are approxi-
mately 30 kbp apart on LG V, with four protein-coding genes
between them, including the neural gene ric-7 (Hao et al., 2012;
Maduro et al., 2005a). We will refer to the control transgene inser-
tions as Si[end-1(þ)] and Si[end-3(þ)]. Where the MED sites have
been mutated in a transgene, this will be indicated as in end-1
(MED) or end-3(MED). To refer to individual MED binding sites, a
notation such as end-3(1234þ) would indicate that the ﬁrst
three sites have been mutated while the fourth is intact. The end-1
(ok558) end-3(ok1448) V double null mutant background, common to
all of the strains, will be denoted as end-1,3().
We ﬁrst established that the single-copy transgenes exhibit
normal levels of end-1 and end-3 expression by quantifying mRNA
levels. The expression patterns for both genes and for elt-2 were
consistent between N2 and end-1,3(); Si[end-1(þ)]; Si[end-3(þ)]
(Fig. 2E) and did not display any of the changes in timing or levels
that occur when these genes are perturbed (Raj et al. 2010; ACW
and SAR, unpublished observations). Hence, these transgene
locations do not exhibit any gross differences in timeliness or
degree of transcription.
We next tested the ability of the wild-type transgenes to com-
plement the end-1,3() background in various conﬁgurations, as
summarized in Table 1. As expected, the control end-1,3(); Si[end-1
(þ)]; Si[end-3(þ)] strain made gut 100% of the time (n4500;
Fig. 3A). We found that if only the Si[end-1(þ)] transgene is present
in the end-1,3() background, 96% of embryos made gut (n¼133;Fig. 2. Construction of wild-type and MED-site mutated end-1 and end-3 single-copy t
region up to the coding region of the nearest upstream gene is taken to be the 5' end of
and/or END-3), MED-1, SKN-1, PAL-1 and POP-1 are shown as described in Table S1. T
proximal POP-1 site in end-1 is adjacent to Helper sequences (Bhambhani et al., 2014). (B
were inserted downstream of Cb-unc-119(þ) in a vector to target the Mos insertion sit
appropriate to the insertion site. These insertion sites have been previously found to be
maternally expressed (Frokjaer-Jensen et al., 2012). (C) Structure of the MED-1 binding si
or end-3. At least two base pairs were mutated within the GTATACT invariant core. The l
not alter any other known binding sites, including those of the POP-1 Helper sequences
TATA consensus (Grishkevich et al., 2011; Lowry et al., 2009). (E) Expression levels in tra
Lines across each dot represent a 95% conﬁdence interval for the expression level of tha
25 °C using data from a prior report (Bao et al., 2006).Fig. 3C). This genotype is equivalent to a single end-3 mutant, which
we have previously reported as 95% making gut (Maduro et al.,
2005a). This result is informative: an extrachromosomal multicopy
array containing end-1(þ) restores gut to 100% of end-1,3() and
end-3() embryos (Maduro et al., 2005a), showing that greatly
increased dosage of end-1 overcomes any requirement for end-3. In
the converse experiment, the end-1,3(); Si[end-3(þ)] strain makes
gut 100% of the time just as end-1 single mutants do (Fig. 3D)
(Maduro et al., 2005a). These results suggest that the single-copy
end-1 and end-3 transgenes show near-normal levels of end-1 and
end-3 expression, assayed by both rescue of endoderm and accu-
mulation of transcripts, and are therefore good proxies for the
endogenous end genes.
MED sites in the end genes are important for gut speciﬁcation in a
chromosomal context
We next introduced the Si[end-1(MED)] and Si[end-3(MED)]
transgenes together into the end-1,3() background to generate a
strain, end-1,3(); Si[end-1(MED)]; Si[end-3(MED)] that we
will refer to as end-1,3(MED). We observed gut in 75% (n¼459)
of end-1,3(MED) embryos (Table 1 and Fig. 3B). This is within the
range of 50–85% previously reported for med-1,2() and med-1,2
(RNAi) embryos (Goszczynski and McGhee, 2005; Maduro et al.,
2007, 2001), consistent with a partial requirement of the MEDs for
endoderm speciﬁcation.
In using end transgenes unlinked from the endogenous end-1
and end-3 genes, we considered that the presence of the endo-
genous though non-functional loci might interfere with expressionransgenes. (A) Promoter structure of the end-1 and end-3 genes. The complete 5'
the promoters. Putative binding sites for GATA factors (presumptive sites for END-1
he cluster of MED-1 binding sites in each gene is indicated by an asterisk (*). The
) General structure of MosSCI-mediated targeting constructs. Either end-1 or end-3
e in ttTi5605 II (for end-1) or ttTi4348 I (for end-3); homology arms (L and R) were
compatible with normal expression of other transgenes, including those that are
tes (Lowry et al., 2009). (D) Mutations introduced at the MED binding sites in end-1
ocation of each site is given in bp relative to the ATG start codon. The mutations do
(Bhambhani et al., 2014) or of a putative TATA box, as the MED site differs from the
nscripts per embryo of end-3, end-1 and elt-2. Each dot represents a single embryo.
t embryo. Minutes after fertilization is based on mapping to nuclei count to time at
Fig. 3. Polarized light micrographs showing gut granules in end-1(ok558) end-3(ok1448) double mutants transgenic for single-copy insertions of end transgenes. Percentages
indicate proportion of embryos containing gut. (A) Control (wild-type) Si[end-1(þ)] and Si[end-3(þ)]. (B) Single-copy end-1 and end-3 transgenes in which all MED binding
sites were mutated, end-1,3(); Si[end-1(MED)]; Si[end-3(MED)], a strain referred to as end-1,3(MED) in the text. (C) Si[end-1(þ)] alone. In panels B and C, some
embryos lacking gut are indicated with arrows. (D) Si[end-3(þ)] alone. (E) Si[end-1(MED)] alone. Very few embryos contain gut granules. (F) Si[end-3(MED)] alone, in
which no embryos contain endoderm.
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through competition for a limiting factor. To test for such an effect,
we crossed the end transgenes into a strain carrying itDf2, a deﬁ-
ciency that removes the ends and several hundred other genes
(Zhu et al., 1997). We found that while 100% of itDf2; Si[end-1(þ)];
Si[end-3(þ)] embryos made gut, 75% (n¼198) of itDf2; Si[end-1
(MED)]; Si[end-3(MED)] embryos did (Table 1). These results
are in agreement with those obtained with the end-1(ok558) end-3
(ok1448) double mutant background (p¼0.96 and χ2 test), sug-
gesting that the endogenous end promoters do not interfere with
expression of the single-copy transgene end genes used here. One
corollary of this result is that no other genes deleted by itDf2 are
necessary to specify endoderm, as single-copy transgenes of end-1
and end-3 are sufﬁcient to restore gut speciﬁcation to all embryos.
Additionally, as itDf2 does not modify the amount of partial gut
speciﬁcation seen in the end-1,3(MED) strain, no genes deleted
by itDf2, apart from end-1 and end-3, appear to make a signiﬁcant
zygotic contribution to gut speciﬁcation.
We next examined MED site requirements when only one of
end-1 or end-3 is present. As noted above, an end-1,3(); Si[end-1
(þ)] strain makes gut 96% of the time, and an end-1,3(); Si[end-3
(þ)] strain makes gut 100% of the time (Fig. 3C and D). Mutation of
the MED sites when only end-1 is present (transgene Si[end-1
(MED)]) results in 28% of embryos making gut (n¼98; Fig. 3E).
This is similar to simultaneous mutation of both med genes and
end-3, which we have previously observed to result in gut speci-
ﬁcation in 37% of embryos (n¼258, p¼0.11 and χ2 test) (Maduro
et al., 2007). When the MED sites are mutated in end-3 in the
absence of end-1, to make end-1,3(); Si[end-3(MED)], gut is
never made (n¼93; Fig. 3F), similar to the 3% of embryos we
observed to make gut in a med-1,2(); end-1() triple mutant
(n¼121; p¼0.26 and Fisher's Exact Test). To determine the mini-
mum number of MED sites that would restore end-3 activation, we
examined gut rescuing ability of single-copy end-3 transgenes in
which one, three, or four of the MED sites were mutated. When
the fourth site, most proximal to the start of transcription, is
mutated, gut is still made 100% of the time (n¼253), and when the
ﬁrst three sites are mutated, gut is made 85% of the time
(n¼271; Table 1). Hence, even one MED binding site is usually
sufﬁcient for end-3 to specify endoderm in the absence of end-1.
We previously showed that a multicopy end-1 "minimal" GFPreporter array requires at least two MED sites for activation
(Broitman-Maduro et al., 2005). This suggests that there is at least
one other input into end-3 activation in addition to the MEDs. By
itself, this input is not sufﬁcient to activate end-3 enough to specify
gut when both end-1 and the MED sites in the end-3 promoter are
absent. Overall, these results show that when a single end gene is
present, the MED binding sites become important for end
expression, with end-3 showing the strongest requirement.
Finally, we tested combinations of end transgenes in which one
end gene carries MED sites and the other does not. Both cases, end-
1,3(); Si[end-1(MED)]; Si[end-3(þ)] and end-1,3(); Si[end-1
(þ)]; Si[end-3(MED)], exhibited 100% speciﬁcation of gut (Table 1).
POP-1 and PAL-1 become necessary for E speciﬁcation when MED
sites are mutated
The existence of parallel inputs into end activation is supported
by the observation that gut speciﬁcation occurred in 75% of
embryos when the MED binding sites were mutated in both end-1
and end-3. Consistent with this observation, the end promoters
contain binding sites for the maternal factors SKN-1, POP-1 and
PAL-1 (Fig. 2, Table S1) (Bhambhani et al., 2014; Blackwell et al.,
1994; Korswagen et al., 2000; Lei et al., 2009). Of these, SKN-1
accounts for the majority of input into end activation, as loss of
skn-1 activity results in a failure of gut speciﬁcation in 65–80% of
embryos (Bowerman et al., 1992; Huang et al., 2007; Maduro et al.,
2005b). Unlike skn-1, loss of pop-1 or pal-1 does not exhibit a
signiﬁcant loss of endoderm speciﬁcation (Hunter and Kenyon,
1996; Lin et al., 1995; Maduro et al., 2005b). Rather, input by POP-1
and PAL-1 can be inferred genetically by enhancement of a back-
ground in which skn-1 is reduced or absent, as simultaneous
depletion of skn-1 with pop-1 and/or pal-1 greatly increases the
severity of the endoderm speciﬁcation defect over loss of skn-1
alone (Huang et al., 2007; Maduro et al., 2007). This is consistent
with a model in which SKN-1 provides the major input while POP-
1 and PAL-1 provide parallel inputs.
We tested the contributions of SKN-1, POP-1 and PAL-1 in the
absence of MED sites by depleting them individually by bacteria-
mediated RNAi (Kamath and Ahringer, 2003) in the control and
end-1,3(MED) strains. RNAi of skn-1 in the control strain resulted
in speciﬁcation of gut 30% of the time (n¼454), similar to skn-1
end-1,3(+) end-1,3(MED-)
Fig. 4. Synergistic loss of endoderm occurs in bacterial feeding-based RNAi targeting skn-1, pop-1 or pal-1 in end-1,3() embryos transgenic for end transgenes. Percentages
indicate proportion of embryos containing gut. Left column: control Si[end-1(þ)] and Si[end-3(þ)] transgenes in an end-1,3() background. Right column: Si[end-1(MED)
and Si[end-3(MED)] transgenes in an end-1,3() background.
Table 2
Endoderm speciﬁcation in skn-1, pop-1 and pal-1 RNAi-treated transgenic strains.
Genotype and RNAi treatment % of embryos with gut
(n)a
end-1,3(); Si[end-1(þ)]; Si[end-3(þ)] 100% (169)
end-1,3(); Si[end-1(MED)];Si[end-3(MED)] 75% (459)
end-1,3(); Si[end-1(þ)]; Si[end-3(þ)]; skn-1
(RNAi)
30% (454)
end-1,3(); Si[end-1(MED)]; Si[end-3(MED)];
skn-1(RNAi)
21% (522)
end-1,3(); Si[end-1(MED)]; Si[end-3(MED)];
skn-1(RNAi)b
27% (218)
end-1,3(); Si[end-1(þ)]; skn-1(RNAi) 4% (416)
end-1,3(); Si[end-3(þ)]; skn-1(RNAi) 3% (259)
end-1,3(); Si[end-1(þ)]; Si[end-3(þ)]; pop-1
(RNAi)
100% (564)
end-1,3(); Si[end-3(þ)]; pop-1(RNAi) 100% (272)
end-1,3(); Si[end-1(MED)]; Si[end-3(þ)]; pop-1
(RNAi)
99% (225)
end-1,3(); Si[end-3(1þ2þ3þ4)]; pop-1(RNAi) 100% (222)
end-1,3(); Si[end-1(þ)]; Si[end-3(MED)]; pop-1
(RNAi)
6% (489)
end-1,3(); Si[end-3(1234þ)]; pop-1(RNAi) 1% (345)
end-1,3(); Si[end-1(þ)]; pop-1(RNAi) 0% (74)
end-1,3(); Si[end-1(MED)]; Si[end-3(MED)];
pop-1(RNAi)
0% (319)
end-1,3(); Si[end-1(MED)]; Si[end-3(MED)];
pop-1(RNAi)b
5% (352)
end-1,3(); Si[end-1(þ)]; Si[end-3(þ)]; pal-1(RNAi) 100% (400)
end-1,3(); Si[end-3(þ)]; pal-1(RNAi) 100% (370)
end-1,3(); Si[end-1(MED)]; Si[end-3(þ)]; pal-1
(RNAi)
100% (671)
end-1,3(); Si[end-1(þ)]; Si[end-3(MED)]; pal-1
(RNAi)
80% (610)
end-1,3(); Si[end-1(þ)]; pal-1(RNAi) 58% (404)
end-1,3(); Si[end-3(1234þ)]; pal-1(RNAi) 55% (276)
end-1,3(); Si[end-1(MED)]; Si[end-3(MED)];
pal-1(RNAi)
3% (755)
end-1,3(); Si[end-1(MED)]; Si[end-3(MED)];
pal-1(RNAi)b
1% (372)
a Scored as in Table 1.
b Gonadal injection of dsRNA performed as described (Maduro et al., 2005b).
All other knockdowns were by bacterial feeding-based RNAi (Kamath et al., 2001).
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1,3(MED) strain resulted in gut in 21% of embryos (n¼522;
po0.002) (Fig. 4A and B and Table 2). A similar synergistic effectof genetic loss of med-1,2() on skn-1(RNAi) was also observed in
a previous report (Maduro et al., 2007), suggesting that there is
some MED activity that is independent of SKN-1, or that skn-1
(RNAi) does not fully eliminate all med-1,2 expression. The report
of 19% gut made by the progeny of mothers homozygous for the
putative null mutation skn-1(zu67) 25 °C is consistent with the
latter (Bowerman et al., 1992). Either way, as 20% of embryos
lacking both SKN-1 and MED-1,2 regulatory input still make
endoderm, this must be the result of parallel inputs.
The TCF factor POP-1 has a dual role in E speciﬁcation: It
represses end-1 and end-3 in the MS cell, and contributes to Wnt-
dependent activation of end-1 (and possibly end-3) in parallel with
SKN-1/MED-1,2 (Lin et al., 1995; Owraghi et al., 2010; Shetty et al.,
2005). While POP-1-dependent repression of the ends occurs via
POP-1 sites (alone), POP-1-dependent activation requires the nearby
presence of conserved 'Helper' sites through which the POP-1/SYS-1
complex likely binds (Bhambhani et al., 2014; Robertson et al., 2014;
Shetty et al., 2005). The end-1 promoter contains a nearby POP-
1þHelper site (Fig. 2 and Table S1), and these sites mediate a posi-
tive contribution of POP-1 to end-1 activation (Bhambhani et al.,
2014; Shetty et al., 2005). In contrast, the end-3 promoter has POP-1
sites and putative Helper sites, though the best consensus Helper
sites are not near the POP-1 sites (Fig. 2 and Table S1) (Robertson
et al., 2014). To test the importance of POP-1 in E speciﬁcation in the
absence of the MED binding sites, we depleted pop-1 by RNAi in
control strains and those with various end-1 or end-3 transgenes
(Table 2). While pop-1(RNAi) of the control strain resulted in endo-
derm 100% of the time (n¼564; Fig. 4C), pop-1(RNAi) in the end-1,3
(MED) strain resulted in a failure of gut to be speciﬁed in all
embryos (n¼319, po0.0001; Fig. 4D). Depletion of pop-1 in other
strains showed that compromising MED sites in end-3 alone, with or
without end-1 present, also results in a complete loss of gut (Table 2).
An interesting result is evident in the strain in which end-1 is absent,
but in which end-3 is present with a single MED binding site, strain
end-1,3(); Si[end-3(1234þ)]: Without pop-1(RNAi), this
strain makes gut 85% of the time (n¼271, Table 1), but with pop-1
(RNAi), gut speciﬁcation occurs in 1% of embryos (n¼345;
po0.0001). This shows that when only end-3 is present, and its
promoter retains only a single MED binding site, a positive con-
tribution from POP-1 becomes nearly essential. These results suggest
that in the absence of MED binding sites, POP-1/SYS-1 make a
stronger contribution to gut speciﬁcation than SKN-1.
M.F. Maduro et al. / Developmental Biology 404 (2015) 66–7974The Caudal-like regulator PAL-1 is essential for speciﬁcation of
the C and D blastomeres (Hunter and Kenyon, 1996). PAL-1 protein
is present in E, and may be more stable than SKN-1, as PAL-1 is
detectable in E and its daughters Ea and Ep, while SKN-1 becomes
undetectable after E has divided (Bowerman et al., 1993; Hunter
and Kenyon, 1996). We have previously shown that in strains
partially compromised for endoderm speciﬁcation, simultaneous
depletion of pal-1 results in a further loss of gut (Maduro et al.,
2007). Consistent with direct regulation of end-1 by PAL-1, the
end-1 promoter contains a single PAL-1 binding site (Fig. 2A and
Table S1) (Lei et al., 2009). The end-3 promoter contains a site that
matches the optimal PAL-1 binding site in 8 of 9 base pairs and
includes the Caudal binding site (Fig. 2A). We hypothesized that in
the absence of the MED binding sites, it should be possible to
detect PAL-1-dependent input into endoderm speciﬁcation with
pal-1(RNAi). Consistent with this prediction, while depletion of
pal-1 by RNAi in the control strain resulted in 100% gut speciﬁ-
cation (n¼400; Fig. 4E), pal-1(RNAi) in the strain lacking MED sites
in end-1 and end-3 speciﬁed gut only 3% of the time (n¼755,
po0.0001; Fig. 4F, Table 2). These results conﬁrm that PAL-1
contributes to E speciﬁcation in parallel with MED-1,2.
To conﬁrm that the RNA interference results were not dependent
on the bacteria-mediated RNAi, we injected dsRNA for skn-1, pal-1 or
pop-1 directly into the end-1,3(MED) strain. As shown in Table 2,
results were similar for skn-1(RNAi) [21% vs. 27% with gut] and pal-1
(RNAi) [3% vs. 1%], but we still observed 5% of embryos making gut
with pop-1(RNAi). Hence, we conclude that when the MED sites are
absent from end-1 and end-3, endoderm speciﬁcation becomes more
dependent on POP-1 and PAL-1 than SKN-1.
The E cell frequently generates an abnormal number of gut nuclei
when MED sites are mutated
In wild-type embryos, the E cell generates 20 intestinal cells
(Sulston et al., 1983). We have previously reported that in med-1,2
() embryos that contain gut, the number of gut cells varies from
0 to more than 30 (Maduro et al., 2007). This could be due to the
failure of all med-1,2() embryos to specify MS, which results in
an embryonic arrest at 1- to 1.5-fold elongation (Maduro et al.,
2001), or it could be caused by changes in end-1 and end-3 acti-
vation resulting from loss of MED-1,2 input. To distinguish these
possibilities, we examined the generation of gut cells using andistribution of number of elt-2::GFP nuclei
among embryos making gut
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Fig. 5. Number of gut nuclei becomes highly variable when gut speciﬁcation is partially
elt-2::GFP nuclei as indicated along the bottom-most X-axis; only embryos containing at
highest numeric class for each case. To the left of the histograms, a pie chart shows th
reporter itself does not cause the changes in gut nuclei, as similar strains lacking the repo
able to see similar effects on number of nuclei expressing an integrated pept-1::mCher
escence. (B) Example of late-stage end-1,3(MED) embryos with no gut and variable am
four nuclei in the anterior and one in the posterior. Note presence of gut granules (whit
embryo. (E) Number of elt-2::GFP-expressing nuclei at various stages during embryonic
strain (open circles).integrated elt-2::GFP reporter (Fukushige et al., 1998), reasoning
that the strains generated here speciﬁcally affect only the ability of
the MEDs to activate end-1 and end-3, creating the equivalent of a
med-1,2() phenotype that is restricted to the E lineage.
We scored the number of elt-2::GFP nuclei in late-stage
embryos as shown in Fig. 5A. As expected, controls exhibited the
wild-type number (range of 19–21, x¯¼20.0þ0.1, n¼34). Among
embryos with gut, the numbers of elt-2::GFP nuclei varied from
3 to 30 in the end-1,3(); Si[end-1(þ)] strain, though with a mean
similar to the control (x¯¼19.7þ5.7, n¼49). This is expected, as
this strain should behave similarly to the single end-3(ok1448)
mutant, which we previously reported to form aberrant numbers
of elt-2::GFP nuclei (Maduro et al., 2007).
We next evaluated elt-2::GFP in end-1,3(MED) embryos. As
predicted by the med-1,2() phenotype, we observed variations in
the number of elt-2::GFP nuclei among embryos with gut
(x¯¼12.9þ0.8, n¼85). Overall, 93% of embryos had a non-wild-type
number of elt-2-expressing cells, which is consistent with the 93–
95% of med-1,2() embryos that fail to generate 20 elt-2::GFP nuclei
(Maduro et al., 2007). Hence, the aberrant numbers of gut cells seen
in terminal med-1,2() embryos can be attributed to a failure of
MED-1,2 to provide input into end-1 and end-3, and not because
speciﬁcation of MS, and overall morphogenesis, also fail to occur.
In the aforementioned strains experiencing partial gut speciﬁ-
cation, a more severe inability to specify gut appears to predict a
greater likelihood of aberrant numbers of elt-2::GFP(þ) nuclei. To
test whether this correlation persists when the proportion of
embryos producing gut is extremely low, we examined elt-2::GFP
in the end-1,3(); Si[end-1(MED)] strain, which produced gut in
28% of embryos. Many of these embryos have relatively small
patches of gut granule-like material (e.g. compare Fig. 3C and E).
Consistent with this, the numbers of elt-2::GFP nuclei among
embryos with gut were generally low, with a range of 1–23 nuclei
(x¯¼7.3þ0.6, n¼79). We conclude that a reduced likelihood of gut
speciﬁcation results in fewer embryos producing gut, and also
fewer elt-2(þ) nuclei when gut is made. This provides strong
evidence that gut speciﬁcation cannot be described as an "all-or-
none" phenomenon when regulation of end-1 and/or end-3 is
partially compromised.Number of elt-2::GFP Nuclei by Stage
in control and end-1,3(MED-) embryos
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hypomorphic embryos
The basis for the aberrant numbers of gut nuclei in speciﬁca-
tion-compromised strains could be the result of changes in the
division pattern of the E lineage, i.e. the E cell divides too few or
too many times, or it may be that in some embryos, E generates a
mixture of gut and non-gut cells. Several lines of evidence argue
for both as contributing factors. First, the appearance of elt-2::GFP
nuclei in late-stage embryos is similar in size to controls, and not
to the nuclei of early-stage embryos, which are much larger
(Fig. 5B–D and data not shown). Second, the elt-2::GFP(þ) nuclei
often appear in different positions in the embryo, suggesting that
cells with distinct origins within the E lineage have separately
adopted a gut fate. For example, an arrested larva with ﬁve elt-2::
GFP nuclei (Fig. 5C) contains a cluster of four elt-2::GFP nuclei in
the anterior and a single such nucleus in the posterior. Hence,
when there are much fewer than 20 gut cells in an embryo, this
may result from the acquisition of an intestine fate from only some
of the descendants of E, and not all of them.
A failure of late-stage embryos to show an intestine identity
among all E descendants could occur in one of two ways. The early
E lineage cells could always acquire an intestine progenitor iden-
tity, but some of them lose this identity over time and adopt an
alternate fate; alternatively, acquisition of an intestine fate may
occur later within the E lineage. To distinguish these possibilities,
we examined ﬁxed time points of control and end-1,3(MED)
embryos for their expression of elt-2::GFP. Whereas controls
exhibited expression appropriate to embryonic stage, many end-
1,3(MED) embryos had fewer or no elt-2::GFP expressing cells
compared to controls (Fig. 5E). We have also examined individual
embryos over time, and found that a majority exhibit delayed and
weaker onset of elt-2::GFP expression, and when elt-2::GFPEgl,Ste
end-1,3(M
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Fig. 6. Post-embryonic defects are apparent in speciﬁcation-compromised strains. (A)
controls, surviving adults of the end-1,3(MED) strain experience an average developm
animals were scored. (C) Venn diagrams showing appearance of phenotypes as a percen
proportion to the percentage. Egl¼egg laying defective; Ste¼sterile; Pvl¼protruding vu
Sma¼small body size; Dpy¼dumpy body shape; WT¼wild-type (normal) appearance.
ﬂuorescence of a pept-1::mCherry::H2B reporter in each of the two strains. The bar char
gut nuclei and a higher mean overall. 24 control and 50 end-1,3(MED) animals were sco
normal adults are approximately 1 mm long.expression was observed, it persisted in the descendants of the
expressing cells (HC and MM, data not shown; a more detailed
analysis will be presented elsewhere). These results suggest that
activation of elt-2 and commitment to an E fate become delayed
and stochastic within the E lineage when end-1 and end-3 lack
MED binding sites.
Adults derived from surviving end-1,3(MED) transgenic embryos
exhibit pleiotropic defects
The current model for gut speciﬁcation is that elt-2 activation,
reinforced by elt-7, determines intestinal fate which is then
maintained via positive autoregulation for the life of the animal
(Fukushige et al., 1999; McGhee et al., 2009; Sommermann et al.,
2010). An important unanswered question is whether endoderm
differentiation is robust to delayed activation of elt-2: After
expression of end-1 and end-3 has disappeared, does ELT-2 always
drive a normal program of intestinal differentiation?
To examine this question, we examined adults of the end-1,3
(MED) and end-1,3(); Si[end-1(MED)] strains, as these repre-
sent mild and severe effects on speciﬁcation, respectively (Fig. 5),
and they also produce some embryos that survive to become fertile
adults. As summarized in Fig. 6, many surviving adults exhibited a
variety of phenotypes including a short body size (Dpy), egg laying
inability (Egl) and sterility (Ste), often along with other morpholo-
gical defects that were not seen in control animals (Fig. 6A). The
defects occurred more frequently in the end-1,3(); Si[end-1
(MED)] surviving adults than end-1,3(MED), suggesting that
the occurrence of the defects correlates with the severity of the
embryonic gut speciﬁcation defect.
Most end-1,3(MED) embryos exhibited aberrant numbers of
gut nuclei, including some with many more than the wild-type
number of 20 (Fig. 5A). We hypothesized that variability in gutED-)
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examined control and end-1,3(MED) L4 animals carrying a pept-
1::mCherry::H2B reporter. As shown in Fig. 6D, in the control
strain we counted a mean of 33.970.2 gut nuclei with a range of
32–38 (n¼29). This is consistent with the expected number of 34
in adults, as 14 of the 20 L1 gut nuclei undergo a further division
prior to the L2 stage (Sulston and Horvitz, 1977). The end-1,3
(MED) strain showed a mean of 38.970.3 gut nuclei with a
range of 31–55 (n¼50; po106). Hence, adult survivors of this
strain display aberrant numbers of gut nuclei with an average
increase of approximately ﬁve nuclei over the control. We note
that no animals were found with fewer than 30 gut nuclei, sug-
gesting that larvae with less than the wild-type number of 20 do
not survive to adulthood.
As egg-laying defects and sterility are induced when normal
animals are deprived of food (Seidel and Kimble, 2011), we hypo-
thesized that the aforementioned suite of defects results from a
defective ability of the intestine to provide adequate nutrition to the
animal, resulting in a developmentally-induced caloric restriction
(CR). Consistent with this, preliminary data suggest that the end-1,3
"hypomorphic" adults exhibit abnormally high lipid stores as stained
by Oil Red O, even among adults with apparently normal morphol-
ogy, and despite being fed ad libitum (GBM and MM, unpublished
observations). Increased lipid stores have been observed in adult C.
elegans following CR during larval development (Palgunow et al.,
2012). In that study, animals given lower amounts of E. coli during
larval development also exhibited a developmental delay of 4–6 h
between embryogenesis and adulthood. To test for a possible
developmental delay, we timed development of control and end-1,3
(MED) animals to adulthood. While control animals progressed to
young adulthood over an average of 49.170.1 h (n¼130), surviving
end-1,3(MED) adults took an average of 54.670.3 h (n¼90;
po1037), representing a delay of 5.5 h, similar to the delay seen
in wild-type animals subjected to larval CR (Palgunow et al., 2012).
Finally, to be sure that these defects are not peculiar to the
arrangement of transgenes that we have used here, we examined
surviving adults of med-1(ok804); end-3(ok1448) double mutants,
which make gut 42% of the time, and end-3(ok1448) and end-3
(zu247) single mutants, which each make gut 95% of the time
(Maduro et al., 2007). We observed similar adult phenotypes in
both cases, though at a lower frequency in the end-3 single
mutants (data not shown). Hence, the more compromised endo-
derm speciﬁcation is overall, the more likely that surviving adults
will exhibit defects. These results suggest that a failure to activate
endoderm speciﬁcation in a timely manner causes defects in
intestinal differentiation.Discussion
Speciﬁcation of the endoderm in C. elegans has been a useful
model to study how a gene regulatory network directs cell type
identity, starting with maternal factors through to terminal reg-
ulators (Maduro, 2008). Prior analyses have revealed that speciﬁ-
cation results from the parallel activities of multiple factors that
impinge on activation of end-1 and end-3 (Bowerman et al., 1992;
Lin et al., 1995; Maduro et al., 2005a, 2005b; Shetty et al., 2005).
Here we have further elucidated the contribution of the divergent
GATA factors MED-1 and MED-2 to speciﬁcation of endoderm, by
mutating their binding sites in single-copy transgenes of end-1
and end-3 and inserting these into an end-1 end-3 double-mutant
background. We have found that loss of MED-1,2-dependent input
into the end genes results in delayed elt-2 activation, lineage
defects in embryos, and phenotypes in surviving adults that are
suggestive of defects in intestine function. We conclude from these
results that MED-1 and MED-2 promote robust activation of end-1and end-3, and hence of elt-2, to promote proper intestinal spe-
ciﬁcation and differentiation.
POP-1 and PAL-1 function in parallel to SKN-1/MED-1,2 in endoderm
speciﬁcation
Building on prior work establishing input of POP-1 and PAL-1 in
E speciﬁcation in parallel with SKN-1 (Maduro et al., 2005b; Shetty
et al., 2005), we have provided additional evidence that SKN-1,
POP-1 and PAL-1 together account for endoderm speciﬁcation that
occurs in the absence of the MED binding sites, and shown that
the relative contributions of these factors are different. In other-
wise wild-type embryos, Wnt-signaled POP-1 and Caudal/PAL-1
are individually dispensable for endoderm speciﬁcation (Table 2)
(Hunter and Kenyon, 1996; Lin et al., 1995). The end-1,3(MED)
strain is a compromised background in which regulatory input
from POP-1 and PAL-1 both become nearly essential for endoderm
to be speciﬁed (Table 2). The positive contribution of POP-1 to end-
1 activation requires POP-1 Helper sites in the end-1 promoter
(Bhambhani et al., 2014; Shetty et al., 2005). While the end-3
promoter contains POP-1 sites, the only nearby sequences to these
are not a perfect match to the consensus Helper site (Fig. 2 and
Table S1) (Robertson et al., 2014). Here we have found evidence
that POP-1 may nonetheless act positively on end-3, as pop-1
(RNAi) can enhance the gut speciﬁcation defect of an end-1,3()
strain carrying only the end-3 transgene with a single MED site, in
strain end-1,3(); Si[end-3(1234þ)] (Tables 1 and 2): with
no RNAi treatment, this strain makes gut in 85% of embryos
(n¼271), while pop-1(RNAi) reduces this to 1% (n¼345).
Our results conﬁrm that Caudal/PAL-1, which speciﬁes the C
and D fates, contributes to E speciﬁcation as we reported pre-
viously (Maduro et al., 2005b). The positive role of PAL-1 in
endoderm is now supported by multiple lines of evidence,
including the presence of PAL-1 protein in the early E lineage
(Hunter and Kenyon, 1996), the presence of an optimal binding site
for PAL-1 in the end-1 promoter (Fig. 2A), the ability of pal-1
knockdown to enhance gutlessness in skn-1(RNAi) and end-3
mutants (Maduro et al., 2005b), and the enhancement of the gut
speciﬁcation phenotype of the end-1,3(MED) and similar strains
by pal-1(RNAi) (this work). Our results suggest that, like POP-1,
PAL-1 acts primarily through end-1.
Together, POP-1 and PAL-1 provide regulatory input in parallel
with SKN-1/MED-1,2. The gut defect of skn-1(RNAi) was enhanced
only slightly when MED sites were deleted, as the proportion of
embryos making gut went from 30% in skn-1(RNAi) in the control
strain to 21% in the end-1,3(MED) strain (Fig. 4A and B; Table 2);
however this may be attributable to an inability of RNAi to com-
pletely eliminate endogenous skn-1 mRNA. The results are none-
theless consistent with the fact that SKN-1 is essential for
expression of med-1 and med-2 (Maduro et al., 2001). We pre-
viously observed that knockdown of both pop-1 and pal-1 together
by gonadal injection of dsRNA still resulted in speciﬁcation of gut
in all progeny embryos (Maduro et al., 2005b), which suggests that
while POP-1 and PAL-1 work in parallel with SKN-1/MED-1,2-
dependent activation, they do not synergize with each other. One
interpretation of this is that POP-1 and PAL-1 may work coop-
eratively, as may be the case in the C lineage during muscle spe-
ciﬁcation (Fukushige and Krause, 2005).
Robustness of E speciﬁcation requires MED-1,2
Our analysis of end-1,3(MED) embryos found that among
embryos containing gut, the number of elt-2::GFP nuclei fre-
quently deviated from the 20 expected in the wild type. Obser-
vation of developing embryos showed that that onset of elt-2
expression, and hence commitment to intestinal fate, was delayed
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reporters became weakened in med-1,2() embryos (Fig. 1B–E), a
reasonable hypothesis is that the amounts of END-1 and END-3
protein made in the absence of MED-1,2 regulatory input are not
high enough to robustly activate elt-2 until the E cell has com-
pleted one or more rounds of cell division. In a separate paper, we
report that when the MED sites are mutated, the expression levels
of end-3 are curtailed and end-1 becomes highly variable, leading
to delayed and less robust elt-2 activation (ACW and SAR,
unpublished observations). We can rule out an effect of the single-
copy transgenes, as a delay or absence of onset of an integrated elt-
2::GFP reporter also occurs in med-1,2() and med-1(); end-3
() embryos (data not shown). These results are most consistent
with a model in which MED-1,2 act on end-1,3 to assure a timely
commitment to an endoderm fate. We have previously observed
aberrations in numbers of elt-2::GFP nuclei in skn-1(RNAi), med-1
(); end-3() double mutant and med-1,2() double mutant
embryos, but it was not possible to separate out possible cell non-
autonomous effects resulting from loss of MED function in the MS
lineage (Maduro et al., 2007). We and others have seen less fre-
quent aberrations in the division pattern of cells in the early E
lineage in single end-3 mutants, but these specify endoderm at a
relatively high rate (95%) and hence onset of elt-2 expression is
likely not as severely affected (Boeck et al., 2011; Maduro et al.,
2005a). In other backgrounds, such as gain-of-function mutations
in cdc-25.1, the E lineage produces supernumerary embryonic
nuclei with no other apparent phenotypes (Clucas et al., 2002;
Kostic and Roy, 2002), consistent with ﬁndings that show that
speciﬁcation and the pattern of cell divisions can be uncoupled
(Nair et al., 2013).
If only some cells in the E lineage adopt an intestine fate in
hypomorphic speciﬁcation strains, what happens to those cells that
do not? Our prior work has established that when end-1 and end-3
are both mutated, E adopts the fate of the C cell and makes meso-
dermal and ectodermal cells, similar to the fate of the E cell in skn-1-
depleted embryos that fail to make gut (Bowerman et al., 1992;
Maduro et al., 2005a; Owraghi et al., 2010; Zhu et al., 1997). The C
fate is speciﬁed by Caudal/PAL-1, which is also found in the nucleus
of E and its daughters (Hunter and Kenyon, 1996). This suggests that
there is potential for non-endoderm E descendants to make C-type
tissues (muscle and hypodermis) in at least some end-1,3(MED)
embryos that make partial guts. While we did not directly evaluate
the fate of presumptive transformed E descendants, we observed
ectopic, enclosed hypodermis-lined cavities in some terminal
embryos with a partial gut (not shown), similar to structures
observed in end-1,3() embryos (Owraghi et al., 2010) and in
embryos lacking skn-1 or med-1,2 function (Bowerman et al., 1992;
Maduro et al., 2001). Hence, it is likely that the non-endodermal Eend-1
+
end-3
elt-2
Fig. 7. Speculative model of how the combined activities of end-1 and end-3 must
reach a threshold for completely normal E lineage development. Below that
threshold, speciﬁcation may still occur, but it becomes stochastic, in some cases
allowing only a subset of E descendants to adopt an intestine fate. Those that have
made a relatively normal gut may manifest defects in intestine function at the adult
stage. In the complete absence of end-1 and end-3 together, gut speciﬁcation fails
(Owraghi et al., 2010).descendants in hypomorphic gut speciﬁcation strains adopt fates
consistent with the complete absence of end-1 and end-3.
As shown in Fig. 7, we propose that the loss of the MED binding
sites makes endoderm speciﬁcation highly sensitive to stochastic
differences in other upstream contributions to end-1,3 activation,
which in turn affects which cells in the E lineage activate elt-2 to a
sufﬁcient degree to commit to an intestine fate. In this model, E
speciﬁcation is still subject to a threshold of [END-1þEND-3]
activity, but that threshold can no longer be reliably reached
within the ﬁrst few cell cycles of the E lineage when end-1 and
end-3 lack regulatory input from MED-1,2. This results in a loss of
the robustness of intestine precursor speciﬁcation, which also
compromises intestine function as discussed below.Adults exhibit phenotypes in "hypomorphic speciﬁcation" strains
Most of the strains in which endoderm speciﬁcation is com-
promised are viable as homozygotes, although many end-1,3
(MED) and end-1,3(); Si[end-1(MED)] animals arrest as
embryos or L1s, even though they contain some gut cells. As wild-
type animals that hatch under starvation conditions arrest devel-
opment in the L1 stage (Baugh, 2013), survival of hypomorphic gut
speciﬁcation animals to the L2 stage selects for those that have a
functional gut. We have found that as adults, these animals may
manifest visible defects in egg laying, morphology and sterility
(Fig. 6A and C). As these defects are correlated with a develop-
mental delay and an overall increase in gut nucleus number
(Fig. 6B and D), it is possible that the presence of excess gut nuclei
causes these defects. However, gain-of-function mutations in cdc-
25.1 result in supernumerary gut nuclei without affecting gut
speciﬁcation, and these were not reported to have morphological
defects or changes in intestine function (Clucas et al., 2002; Kostic
and Roy, 2002). The gut nucleus number defects are also more
extreme in the cdc-25.1(gf) mutants than we have seen: whereas
surviving adults of the end-1,3(MED) strain have an average of
ﬁve more nuclei at the L4 stage, cdc-25.1(gf) animals have as many
as 25 more (Kostic and Roy, 2002). Instead, these phenotypes
may result from abnormal metabolism, as we observed increases
in lipid stores and developmental delay, both of which are con-
sistent with caloric restriction (Palgunow et al., 2012).
Our results raise the possibility that adults surviving hypo-
morphic speciﬁcation can inﬂuence the phenotype of their off-
spring because they have defects in their intestine. This might
occur if these animals inappropriately apportion resources to
oocytes, or through an epigenetic mechanism (Rechavi et al., 2014;
Seidel and Kimble, 2011). However, all of the transgenic strains we
have studied here, including the end-1,3(MED) strain, demon-
strated relatively consistent generation-to-generation stability in
the proportion of embryos that made gut and in the proportion of
adults exhibiting defects. Indeed, we might predict that the
healthiest animals would propagate more efﬁciently to the next
generation through a shorter generation time and production of a
greater proportion of viable embryos. Consistent with this, when
the end-1,3(MED) strain was ﬁrst generated, we measured a
stronger endoderm defect, with 33% of embryos failing to make
gut (n¼223), which is greater than the 25% seen after several
generations (n¼459; po0.02). Furthermore, this strain showed
the same likelihood of gut speciﬁcation as homozygous itDf2; end-
1,3(MED) embryos segregated from itDf2/þ; end-1,3(MED)
mothers, which are hemizygous for the wild-type end-1 and end-3
genes (Table 1). This suggests that laboratory propagation favors
the maintenance of the least affected animals, as opposed to
worsening the phenotype over time.
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The current understanding of the C. elegans endoderm GRN
features transient cell speciﬁcation factors that ultimately activate
a positive feedback of terminal differentiation via elt-2 (Fig. 1A).
The activity of the upstream end-1 and end-3 genes is transient
and occurs when the embryo has fewer than 100 cells (Maduro
et al., 2005a; Zhu et al., 1997). Despite the positive autoregulation
of elt-2 at the end of this network, a small perturbation in acti-
vation of end-1 and end-3, through elimination of what has been
thought to be only a minor regulatory input, is sufﬁcient to pro-
duce a cascade of defects that are visible in surviving adults.
What is the mechanistic basis for the adult gut defects?
Although surviving end-1,3(MED) embryos produce a functional
gut, they may be deﬁcient in an activity that is required for normal
metabolism. As there is no evidence that the meds or ends are
expressed in the adult intestine (McGhee et al., 2007; Pauli et al.,
2006), the simplest interpretation is that reduced end-1 and/or
end-3 activation, as a result of loss of MED-1,2 regulatory input,
propagates an effect through the GRN that leads to intestinal dif-
ferentiation through elt-2. Consistent with this, we have observed
a delay in the embryonic activation of elt-2, the central regulator of
intestine fate, in end-1,3(MED) embryos and similar strains that
are partially compromised for embryonic gut speciﬁcation.
Although surviving adults have apparently normal expression of
an elt-2::GFP reporter, it may be that endogenous elt-2 expression
becomes limiting. However, in a preliminary experiment to test
this hypothesis, we introduced an additional genomic copy of elt-2
(þ) via MosSCI into the end-1,3(MED) background, but failed to
observe an improvement in adult defects (GBM and MM, unpub-
lished observations).
Another explanation for the adult defects might be that delayed
onset of elt-2 expression within the E lineage misses a timely
opportunity to activate particular gut differentiation genes. Indeed,
the intestinal gene glo-1 is activated in the E daughter cells and
remains on for the lifetime of the animal (Hermann et al., 2005),
suggesting its expression is initially activated by END-1,3 and is
maintained by ELT-2. Loss of glo-1 function results in a loss of gut
granules (Hermann et al., 2005), but elt-2::GFP-expressing cells in
end-1,3(MED) animals are always associated with gut granule-like
material, suggesting that glo-1 does eventually become expressed.
Nonetheless, it may be that a delay or reduction of expression of
genes such as glo-1 may initiate a cascade of changes in physiology
that persist through larval development and into adulthood.
Regardless of the molecular basis for the effects we have seen,
it is unexpected that intestinal gene expression does not become
properly remodeled during postembryonic development, long
after speciﬁcation has occurred. One interpretation is that the
endoderm GRN has been made robust in its most upstream
components, rather than throughout the network. This is con-
sistent with the diverse set of parallel inputs that participate in
activation of end-1 and end-3. More generally, we propose that in
any metazoan system in which progenitors acquire tissue type
identity through such networks, it is possible that "hypomorphic"
speciﬁcation of a cell type results in heterogeneous differentiated
states that can directly affect the quality of terminal development.
This ﬁnding has implications for other cell speciﬁcation gene
networks in many systems, including the programming of
embryonic stem cells.Acknowledgments
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